|1.||Hall, Frederick L: 5 articles (05/2010 - 08/2002)|
|2.||Gordon, Erlinda M: 5 articles (05/2010 - 08/2002)|
|3.||Hall, F L: 4 articles (07/2001 - 07/2000)|
|4.||Gordon, E M: 4 articles (07/2001 - 07/2000)|
|5.||Chen, Z H: 4 articles (07/2001 - 07/2000)|
|6.||Fornari, Francesca: 3 articles (11/2014 - 07/2007)|
|7.||Giovannini, Catia: 3 articles (11/2014 - 07/2007)|
|8.||Bolondi, Luigi: 3 articles (11/2014 - 07/2007)|
|9.||Gramantieri, Laura: 3 articles (11/2014 - 07/2007)|
|10.||Wang, Yingying: 2 articles (06/2015 - 01/2013)|
|1.||Osteosarcoma (Osteogenic Sarcoma)
09/20/1997 - "Taken together, these studies demonstrate in vivo efficacy of a high-titer antisense cyclin G1 retroviral vector in an animal model of osteosarcoma."
09/20/1997 - "Overexpression of the cyclin G1 (CYCG1) gene is frequently observed in human osteosarcoma cells, and its continued expression is found to be essential for their survival. "
09/20/1997 - "Retroviral vector-mediated transfer of an antisense cyclin G1 construct inhibits osteosarcoma tumor growth in nude mice."
12/01/1995 - "This represents the first demonstration that cyclin G1 is essential for the survival and/or growth of human osteosarcoma cells. "
12/01/1995 - "Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells."
05/01/2010 - "This review describes the major milestones in the clinical development of Rexin-G: from the molecular cloning and characterization of the human cyclin G1 proto-oncogene in 1994, to the design of the first knockout constructs and genetic engineering of the targeted delivery system from 1995 to 1997, through the initial proofs-of-concept, molecular pharmacology and toxicology studies of Rexin-G in preclinical cancer models from 1997 to 2001, to the pioneering clinical studies in humans from 2002 to 2004, which--together with the advancements in bioprocess development of high-potency clinical grade vectors circa 2005 - 2006--led to the accelerated approval of Rexin-G for all solid tumors by the Philippine FDA in 2007 and the rapid progression of clinical studies from 2007 to 2009 to the cusp of pivotal Phase III trials in the US. "
05/01/2015 - "Consistently, p53 target genes including p21, cyclin G1 and Msh2 are reduced in Caspase-2-deficient tumors. "
09/01/2013 - "Cyclin G1 expands liver tumor-initiating cells by Sox2 induction via Akt/mTOR signaling."
05/01/2010 - "Rexin-G, a tumor-targeted retrovector bearing a cytocidal cyclin G1 construct, is the first targeted gene therapy vector to gain fast track designation and orphan drug priorities for multiple cancer indications in the US. "
07/15/2009 - "We have previously shown that miR-122 can regulate the expression of cyclin G1, whose high levels have been reported in several human cancers. "
07/15/1997 - "Moreover, in vivo delivery of high-titer antisense cyclin G1 vector supernatant to the balloon-injured rat carotid artery in vivo resulted in a significant reduction in neointima formation. "
07/15/1997 - "In this study, we examined the inhibitory effects of a concentrated retroviral vector bearing an antisense cyclin G1 gene on aortic SMC proliferation in vitro and on neointima formation in vivo in a rat carotid injury model of restenosis. "
07/01/2001 - "Further, intraarterial instillation of a matrix-targeted, but not a nontargeted, vector bearing an antisense cyclin G1 construct inhibited neointima lesion formation in the injured carotid arteries. "
07/01/2001 - "Long term inhibition of neointima formation in balloon-injured rat arteries by intraluminal instillation of a matrix-targeted retroviral vector bearing a cytocidal mutant cyclin G1 construct."
07/15/1997 - "Downregulation of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation."
|4.||Hepatocellular Carcinoma (Hepatoma)
06/01/2012 - "Cyclin G1 deficiency is associated with reduced incidence of carcinogen-induced hepatocellular carcinoma (HCC), but its function in HCC progression remains obscure. "
09/01/2013 - "In this study, we found that enhanced cyclin G1 expression was associated with drug resistance of hepatoma cells and higher recurrence rate in hepatocellular carcinoma patients. "
11/15/2014 - "Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma."
09/01/2013 - "Forced cyclin G1 expression remarkably enhanced self-renewal and tumorigenicity of hepatoma cells. "
09/01/2013 - "Cyclin G1 has been shown to play a pivotal role in initiation and metastasis of hepatocellular carcinoma. "
|5.||Colorectal Neoplasms (Colorectal Cancer)
08/10/2002 - "Tumor site specific phase I evaluation of safety and efficacy of hepatic arterial infusion of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct as intervention for colorectal carcinoma metastatic to liver."
05/01/2003 - "However, the cyclin B1 expression remains unclear during colorectal carcinogenesis and during later metastasis to lymph nodes, and cyclin G1 expression is not clear in colorectal tumors. "
05/01/2003 - "To clarify the variations of the two cyclins in colorectal tumors, cyclin B1, cyclin G1, p53, and Ki67 were immunohistochemically stained in 22 normal mucosa, 62 adenomas, 17 carcinomas in adenomas, 194 primary carcinomas, and 21 lymph node metastases; and the two cyclins were examined by Western blot in other 10 pairs of normal mucosa and primary carcinomas. "
|4.||Proliferating Cell Nuclear Antigen (PCNA)
|8.||Messenger RNA (mRNA)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)